Navigation Links
Time to Overhaul Australia's Medicines Safety Surveillance System

New medicines should be granted a provisional safety rating until their safety and effectiveness have been proven amongst the wider //population, experts have said in the latest Medical Journal of Australia.

Recent experience with Vioxx and some other prescription medicines, which were withdrawn on safety grounds after marketing, has shown that reliance on pre-marketing trials and voluntary adverse reaction reports from health professionals does not provide adequate protection, said population health expert Associate Professor Chris Kelman, of the National Centre for Epidemiology and Population Health in Canberra, and colleagues.

Trials usually last no more than 12 months, so do not evaluate the increasingly common longterm use of medicines by patients with chronic disorders, Assoc Prof Kelman said. Voluntary adverse reaction reports depend on a health professional making a link between the drug and an adverse event. This system fails when the adverse outcome is common and has other causes, as with heart attacks and Vioxx.

“The current system for evaluating drug safety is outdated,” Assoc Prof Kelman said.

“We propose an expanded and integrated system of medicines regulation for Australia, based on a surveillance system that improves safety monitoring by complementing existing systems, making best use of routinely collected health and pharmaceutical data, and leveraging the power of information technology to link and analyse these data.

“Other countries have established such systems successfully, and Australia has fallen behind the rest of the world, despite the availability of excellent data.”

Under the proposed system, new drugs would be given provisional approval with a ‘Caution – New Medicine’ rating, and be required to undergo strict periodic review using linked population health data-sets.

“Periodic review would be based on accumulated adverse drug reaction reports, recent dru g studies, and commissioned Australian controlled analytical studies using the linked databases,” Assoc Prof Kelman said.

“Provisional approval could be upgraded once significant market experience is gained; for example, a medicine could be given a ‘gold’ safety rating after achieving an agreed benchmark.”

Prominent child health advocate Professor Fiona Stanley, of the Telethon Institute for Child Health Research in Western Australia, agreed that as medical care becomes more complex, it is paramount that Australia modernises its ‘archaic’ system of postmarketing surveillance for new drugs.

“The system proposed by Prof Kelman and colleagues has several advantages,” Prof Stanley said in an editorial written with Dr Eric Meslin, of Indiana University, USA, in the same issue of the MJA.

“However, there are also potential disadvantages associated with such a data linkage system.

“We must be able to demonstrate to the community that linking data for the sake of the public good does not invade their privacy.”

The National Health and Medical Research Council and the Australian Law Reform Commission are both reviewing alternative systems. Prof Stanley said she hopes these reviews will clarify and support the impetus to change.

“We strongly believe that Australia has an opportunity to establish a cutting-edge capacity to monitor its health care system, to avoid a repeat of the type of situation we saw with Vioxx,” she said.

“If society has the capability to better monitor the safety of new drugs, it may be unethical not to do so.

“We think the time has come to expect more … to actively seek to maximise the wellbeing of all citizens. Improved pharmacovigilance is one important step towards this goal.”


Related medicine news :

1. Health Insurance Needs Overhauling: Experts
2. U.S. Child Health System Needs Total Overhaul
3. U.S. Child Health System Needs Total Overhaul
4. Australias Mentally ill, ill at ease with Quality of Care
5. Training in Australias Medical Schools Inadequate
6. Australias Baby Bonus Plan has Increased the Birth Rate
7. Keep Australias GP Workforce Numbers Healthy, AMA Urges
8. Medicines on the move
9. Advent of New, More Effective and Personalized Medicines
10. Be Wary Of Heavy Metal Poisoning From Ayurvedic Medicines
11. Metal In Medicines Can Fight Diseases Effectively
Post Your Comments:

(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: